A genetic bleeding disorder, haemophilia worsens quality of life, can cause deformities and disabilities and in the worst of ...

Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

The petition was filed by Prema Ram who appeared in the Civil Services Examination conducted by the Union Public Service Commission (UPSC) in May this year ...

Pfizer Inc. (NYSE:PFE) ranks among the best set-it-and-forget-it stocks to buy. On June 26, Pfizer Inc. (NYSE:PFE) declared ...

Researchers have created liver tissue that grows its own blood vessels, improving research into hemophilia and liver damage.

“There has been no supply of factor medicines to any state-run hospital since September 2024. As a result, 30 patients from ...

A rare inherited genetic blood disorder that mostly affects men, hemophilia is on the rise, with more than a million men ...

CSL Behring Germany today announced that the first haemophilia B patient in Germany was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Hemophilia Treatment Center at ...

The first haemophilia B patient in Germany has been treated with the one-time gene therapy HEMGENIX at the Hemophilia Treatment Center at Hannover Medical School, CSL Behring Germany has announced.

Early data from the NXTAGE study suggest that NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A (without factor VIII inhibitors).

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and ...

In severe haemophilia B, the cost-effectiveness evidence for marstacimab showed it is a cost-effective option compared with factor 9. So, marstacimab is recommended for preventing bleeding episodes ...